GluCare.Health partners with Novo Nordisk for new obesity programme

GluCare.Health partners with Novo Nordisk for new obesity programme

The model of care for the pilot programme will combine new digital bio-markers alongside existing therapeutics. Utilising wearable and connected technologies, it will offer an unparalleled level of in-patient and data-driven remote care.

It is expected that this model will enhance the levels of care, and eventually treatment outcomes, in comparison to traditional models of care. This innovative partnership will put accountability for outcomes vs costs on the provider, rather than on the insurers or patients, it said.

The partnership will be the region’s first value-based reimbursement model, and will be the first relationship of its kind for Novo Nordisk globally.

The six-month programme, which begins in September, is open to people with obesity - those with a BMI of 30 or above - as well as individuals with a BMI of 27 or above who also have at least one weight-related comorbidity. Once enrolled in the programme, patients will be under the care of GluCare’s multidisciplinary clinical team, which consists of a health coach, a nutritionist, a nurse/patient educator, and an endocrinologist, with the care team additionally monitoring patients virtually.

In this model where disease management is augmented by technology, patients will be provided wearable technology, including IoT (Internet of Things) devices for